On January 4, 2022 Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, reported that the Company will participate virtually at the following upcoming investor conferences (Press release, Verastem, JAN 4, 2022, View Source [SID1234598129]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright BIOCONNECT Virtual Conference; the fireside chat will be made available for on-demand listening beginning Monday, January 10, 2022 at 7:00 a.m. ET
B. Riley Oncology Conference; fireside chat on Friday, January 28, 2022 at 9:30 a.m. ET
A webcast of the fireside chats will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be made available following each event.

On January 4, 2021 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright BioConnect Virtual Conference (Press release, Puma Biotechnology, JAN 4, 2022, View Source [SID1234598128]). The presentation will be available on demand beginning at 7:00 a.m. EST on January 10, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available for replay for 30 days on the Company’s website at www.pumabiotechnology.com.

On January 4, 2022 NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, reported that the Company’s leadership will participate in three upcoming, virtual investor conferences in January 2022 (Press release, Nanobiotix, JAN 4, 2022, View Source [SID1234598127]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event Details:

Oddo BHF Forum 2022
Date: January 6-11, 2022
Format: Virtual one-on-one meetings with investors

H.C. Wainwright Bioconnect Conference
Date: January 10-13, 2022
Format: Corporate presentation
Time: Presentation available starting January 10, 2022 at 7:00 AM (EST) / 1:00 PM (CET)

Biotech Showcase 2022
Date: January 17-19, 2022
Format: Corporate presentation and virtual one-on-one meetings with investors
Time: Presentation available starting at 8:00 AM (PT) / 5:00 PM (CET) on January 10, 2022

The presentations will be accessible on the Events section of the company’s website at www.nanobiotix.com.

On January 4, 2022 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that Robert M. Davis, chief executive officer and president, Dr. Dean Y. Li, president, Merck Research Laboratories, are scheduled to virtually participate in the 40th Annual J.P. Morgan Healthcare Conference on Jan. 10, 2022 at 5:15 p.m. ET (Press release, Merck & Co, JAN 4, 2022, View Source [SID1234598126]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to watch a live video webcast of the presentations at View Source

On January 4, 2022 Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, reported that the Chief Executive Officer of Boundless Bio, Zachary Hornby, will present at the 40th Annual J.P. Morgan Healthcare Conference which will take place virtually (Press release, Boundless Bio, JAN 4, 2022, View Source [SID1234598125]). Presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, January 11, 2022
Time: 2:00 PM – 2:25 PM EST